Conversely, the optimizing of low LDL-C is hardly obtained with evolocumab treatment in homozygous FH patients carrying nonfunctional LDLR due to the LDLR-dependent mechanism of such agents [66]. This evidence concerns the gene LDLR and familial hyperaldosteronism.